Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation

Meng Ju Li, Hsi Che Liu, Hsiu Ju Yen, Tang Her Jaing, Dong Tsamn Lin, Chao Ping Yang, Kai Hsin Lin, Iou Jih Hung, Shiann Tarng Jou, Meng Yao Lu, Chih Cheng Hsiao, Ching Tien Peng, Tai Tsung Chang, Shih Chung Wang, Ming Tsan Lin, Jiann Shiuh Chen, Te Kau Chang, Giun Yi Hung, Kang Hsi Wu, Yung Li YangHsiu Hao Chang, Shih Hsiang Chen, Ting Chi Yeh, Chao Neng Cheng, Pei Chin Lin, Shyh Shin Chiou, Jiunn Ming Sheen, Shin Nan Cheng, Shu Huey Chen, Yu Hsiang Chang, Wan Ling Ho, Yu Hua Chao, Rong Long Chen, Bow Wen Chen, Jinn-Li Wang, Yuh Lin Hsieh, Yu Mei Liao, Shang Hsien Yang, Wan Hui Chang, Yu Mei Y Chao, Der Cherng Liang

研究成果: 雜誌貢獻文章

7 引文 (Scopus)

摘要

Background: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL). We sought to determine the optimal course(s) of reinduction therapy for standard-risk (SR, or “low-risk” in other groups) patients. Also, we evaluated outcomes using triple intrathecal therapy without cranial radiation (CrRT) for central nervous system (CNS) preventive therapy. Procedure: From 2002 to 2012, all newly diagnosed children with ALL in Taiwan were enrolled in Taiwan Pediatric Oncology Group ALL-2002 protocol. SR patients were randomized to receive single or double reinduction courses. The patients enrolled before 2009 received CrRT, while those enrolled later did not. The Kaplan–Meier method was used to estimate survival rates and the difference between two groups was compared by the two-sided log-rank test. Results: In 1,366 eligible patients, the 5-year overall survival (OS) was 81.6 ± 1.1% (standard error) and 5-year event-free survival (EFS) was 74.3 ± 1.2%. In SR patients, the 5-year OS for one and two reinduction courses was 91.6 ± 2.1% and 93.7 ± 1.8%, respectively, and the 5-year EFS was 85.2 ± 2.7% and 89.8 ± 2.3%, respectively. There were no significant differences in survival between these two groups. Patients with MLL or BCR-ABL1 had the worst outcomes: 5-year EFS was 23.4 and 31.8% and 5-year OS was 28.6 and 44.7%, respectively. There was no significant difference in CNS relapse or survival between the era with or without CrRT. Conclusions: For SR patients, one-course reinduction was adequate. Triple intrathecal therapy alone successfully prevented CNS relapse.
原文英語
頁(從 - 到)234-241
頁數8
期刊Pediatric Blood and Cancer
64
發行號2
DOIs
出版狀態已發佈 - 二月 1 2017

指紋

Taiwan
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System
Radiation
Pediatrics
Survival
Disease-Free Survival
Therapeutics
Recurrence
Survival Rate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

引用此文

Treatment for childhood acute lymphoblastic leukemia in Taiwan : Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. / Li, Meng Ju; Liu, Hsi Che; Yen, Hsiu Ju; Jaing, Tang Her; Lin, Dong Tsamn; Yang, Chao Ping; Lin, Kai Hsin; Hung, Iou Jih; Jou, Shiann Tarng; Lu, Meng Yao; Hsiao, Chih Cheng; Peng, Ching Tien; Chang, Tai Tsung; Wang, Shih Chung; Lin, Ming Tsan; Chen, Jiann Shiuh; Chang, Te Kau; Hung, Giun Yi; Wu, Kang Hsi; Yang, Yung Li; Chang, Hsiu Hao; Chen, Shih Hsiang; Yeh, Ting Chi; Cheng, Chao Neng; Lin, Pei Chin; Chiou, Shyh Shin; Sheen, Jiunn Ming; Cheng, Shin Nan; Chen, Shu Huey; Chang, Yu Hsiang; Ho, Wan Ling; Chao, Yu Hua; Chen, Rong Long; Chen, Bow Wen; Wang, Jinn-Li; Hsieh, Yuh Lin; Liao, Yu Mei; Yang, Shang Hsien; Chang, Wan Hui; Chao, Yu Mei Y; Liang, Der Cherng.

於: Pediatric Blood and Cancer, 卷 64, 編號 2, 01.02.2017, p. 234-241.

研究成果: 雜誌貢獻文章

Li, MJ, Liu, HC, Yen, HJ, Jaing, TH, Lin, DT, Yang, CP, Lin, KH, Hung, IJ, Jou, ST, Lu, MY, Hsiao, CC, Peng, CT, Chang, TT, Wang, SC, Lin, MT, Chen, JS, Chang, TK, Hung, GY, Wu, KH, Yang, YL, Chang, HH, Chen, SH, Yeh, TC, Cheng, CN, Lin, PC, Chiou, SS, Sheen, JM, Cheng, SN, Chen, SH, Chang, YH, Ho, WL, Chao, YH, Chen, RL, Chen, BW, Wang, J-L, Hsieh, YL, Liao, YM, Yang, SH, Chang, WH, Chao, YMY & Liang, DC 2017, 'Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation', Pediatric Blood and Cancer, 卷 64, 編號 2, 頁 234-241. https://doi.org/10.1002/pbc.26142
Li, Meng Ju ; Liu, Hsi Che ; Yen, Hsiu Ju ; Jaing, Tang Her ; Lin, Dong Tsamn ; Yang, Chao Ping ; Lin, Kai Hsin ; Hung, Iou Jih ; Jou, Shiann Tarng ; Lu, Meng Yao ; Hsiao, Chih Cheng ; Peng, Ching Tien ; Chang, Tai Tsung ; Wang, Shih Chung ; Lin, Ming Tsan ; Chen, Jiann Shiuh ; Chang, Te Kau ; Hung, Giun Yi ; Wu, Kang Hsi ; Yang, Yung Li ; Chang, Hsiu Hao ; Chen, Shih Hsiang ; Yeh, Ting Chi ; Cheng, Chao Neng ; Lin, Pei Chin ; Chiou, Shyh Shin ; Sheen, Jiunn Ming ; Cheng, Shin Nan ; Chen, Shu Huey ; Chang, Yu Hsiang ; Ho, Wan Ling ; Chao, Yu Hua ; Chen, Rong Long ; Chen, Bow Wen ; Wang, Jinn-Li ; Hsieh, Yuh Lin ; Liao, Yu Mei ; Yang, Shang Hsien ; Chang, Wan Hui ; Chao, Yu Mei Y ; Liang, Der Cherng. / Treatment for childhood acute lymphoblastic leukemia in Taiwan : Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. 於: Pediatric Blood and Cancer. 2017 ; 卷 64, 編號 2. 頁 234-241.
@article{1b90c4b68d29415f90fa621b9b2ee5b3,
title = "Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation",
abstract = "Background: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL). We sought to determine the optimal course(s) of reinduction therapy for standard-risk (SR, or “low-risk” in other groups) patients. Also, we evaluated outcomes using triple intrathecal therapy without cranial radiation (CrRT) for central nervous system (CNS) preventive therapy. Procedure: From 2002 to 2012, all newly diagnosed children with ALL in Taiwan were enrolled in Taiwan Pediatric Oncology Group ALL-2002 protocol. SR patients were randomized to receive single or double reinduction courses. The patients enrolled before 2009 received CrRT, while those enrolled later did not. The Kaplan–Meier method was used to estimate survival rates and the difference between two groups was compared by the two-sided log-rank test. Results: In 1,366 eligible patients, the 5-year overall survival (OS) was 81.6 ± 1.1{\%} (standard error) and 5-year event-free survival (EFS) was 74.3 ± 1.2{\%}. In SR patients, the 5-year OS for one and two reinduction courses was 91.6 ± 2.1{\%} and 93.7 ± 1.8{\%}, respectively, and the 5-year EFS was 85.2 ± 2.7{\%} and 89.8 ± 2.3{\%}, respectively. There were no significant differences in survival between these two groups. Patients with MLL or BCR-ABL1 had the worst outcomes: 5-year EFS was 23.4 and 31.8{\%} and 5-year OS was 28.6 and 44.7{\%}, respectively. There was no significant difference in CNS relapse or survival between the era with or without CrRT. Conclusions: For SR patients, one-course reinduction was adequate. Triple intrathecal therapy alone successfully prevented CNS relapse.",
keywords = "childhood acute lymphoblastic leukemia, CNS prophylaxis, reinduction therapy, standard risk, triple intrathecal therapy",
author = "Li, {Meng Ju} and Liu, {Hsi Che} and Yen, {Hsiu Ju} and Jaing, {Tang Her} and Lin, {Dong Tsamn} and Yang, {Chao Ping} and Lin, {Kai Hsin} and Hung, {Iou Jih} and Jou, {Shiann Tarng} and Lu, {Meng Yao} and Hsiao, {Chih Cheng} and Peng, {Ching Tien} and Chang, {Tai Tsung} and Wang, {Shih Chung} and Lin, {Ming Tsan} and Chen, {Jiann Shiuh} and Chang, {Te Kau} and Hung, {Giun Yi} and Wu, {Kang Hsi} and Yang, {Yung Li} and Chang, {Hsiu Hao} and Chen, {Shih Hsiang} and Yeh, {Ting Chi} and Cheng, {Chao Neng} and Lin, {Pei Chin} and Chiou, {Shyh Shin} and Sheen, {Jiunn Ming} and Cheng, {Shin Nan} and Chen, {Shu Huey} and Chang, {Yu Hsiang} and Ho, {Wan Ling} and Chao, {Yu Hua} and Chen, {Rong Long} and Chen, {Bow Wen} and Jinn-Li Wang and Hsieh, {Yuh Lin} and Liao, {Yu Mei} and Yang, {Shang Hsien} and Chang, {Wan Hui} and Chao, {Yu Mei Y} and Liang, {Der Cherng}",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/pbc.26142",
language = "English",
volume = "64",
pages = "234--241",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment for childhood acute lymphoblastic leukemia in Taiwan

T2 - Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation

AU - Li, Meng Ju

AU - Liu, Hsi Che

AU - Yen, Hsiu Ju

AU - Jaing, Tang Her

AU - Lin, Dong Tsamn

AU - Yang, Chao Ping

AU - Lin, Kai Hsin

AU - Hung, Iou Jih

AU - Jou, Shiann Tarng

AU - Lu, Meng Yao

AU - Hsiao, Chih Cheng

AU - Peng, Ching Tien

AU - Chang, Tai Tsung

AU - Wang, Shih Chung

AU - Lin, Ming Tsan

AU - Chen, Jiann Shiuh

AU - Chang, Te Kau

AU - Hung, Giun Yi

AU - Wu, Kang Hsi

AU - Yang, Yung Li

AU - Chang, Hsiu Hao

AU - Chen, Shih Hsiang

AU - Yeh, Ting Chi

AU - Cheng, Chao Neng

AU - Lin, Pei Chin

AU - Chiou, Shyh Shin

AU - Sheen, Jiunn Ming

AU - Cheng, Shin Nan

AU - Chen, Shu Huey

AU - Chang, Yu Hsiang

AU - Ho, Wan Ling

AU - Chao, Yu Hua

AU - Chen, Rong Long

AU - Chen, Bow Wen

AU - Wang, Jinn-Li

AU - Hsieh, Yuh Lin

AU - Liao, Yu Mei

AU - Yang, Shang Hsien

AU - Chang, Wan Hui

AU - Chao, Yu Mei Y

AU - Liang, Der Cherng

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL). We sought to determine the optimal course(s) of reinduction therapy for standard-risk (SR, or “low-risk” in other groups) patients. Also, we evaluated outcomes using triple intrathecal therapy without cranial radiation (CrRT) for central nervous system (CNS) preventive therapy. Procedure: From 2002 to 2012, all newly diagnosed children with ALL in Taiwan were enrolled in Taiwan Pediatric Oncology Group ALL-2002 protocol. SR patients were randomized to receive single or double reinduction courses. The patients enrolled before 2009 received CrRT, while those enrolled later did not. The Kaplan–Meier method was used to estimate survival rates and the difference between two groups was compared by the two-sided log-rank test. Results: In 1,366 eligible patients, the 5-year overall survival (OS) was 81.6 ± 1.1% (standard error) and 5-year event-free survival (EFS) was 74.3 ± 1.2%. In SR patients, the 5-year OS for one and two reinduction courses was 91.6 ± 2.1% and 93.7 ± 1.8%, respectively, and the 5-year EFS was 85.2 ± 2.7% and 89.8 ± 2.3%, respectively. There were no significant differences in survival between these two groups. Patients with MLL or BCR-ABL1 had the worst outcomes: 5-year EFS was 23.4 and 31.8% and 5-year OS was 28.6 and 44.7%, respectively. There was no significant difference in CNS relapse or survival between the era with or without CrRT. Conclusions: For SR patients, one-course reinduction was adequate. Triple intrathecal therapy alone successfully prevented CNS relapse.

AB - Background: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL). We sought to determine the optimal course(s) of reinduction therapy for standard-risk (SR, or “low-risk” in other groups) patients. Also, we evaluated outcomes using triple intrathecal therapy without cranial radiation (CrRT) for central nervous system (CNS) preventive therapy. Procedure: From 2002 to 2012, all newly diagnosed children with ALL in Taiwan were enrolled in Taiwan Pediatric Oncology Group ALL-2002 protocol. SR patients were randomized to receive single or double reinduction courses. The patients enrolled before 2009 received CrRT, while those enrolled later did not. The Kaplan–Meier method was used to estimate survival rates and the difference between two groups was compared by the two-sided log-rank test. Results: In 1,366 eligible patients, the 5-year overall survival (OS) was 81.6 ± 1.1% (standard error) and 5-year event-free survival (EFS) was 74.3 ± 1.2%. In SR patients, the 5-year OS for one and two reinduction courses was 91.6 ± 2.1% and 93.7 ± 1.8%, respectively, and the 5-year EFS was 85.2 ± 2.7% and 89.8 ± 2.3%, respectively. There were no significant differences in survival between these two groups. Patients with MLL or BCR-ABL1 had the worst outcomes: 5-year EFS was 23.4 and 31.8% and 5-year OS was 28.6 and 44.7%, respectively. There was no significant difference in CNS relapse or survival between the era with or without CrRT. Conclusions: For SR patients, one-course reinduction was adequate. Triple intrathecal therapy alone successfully prevented CNS relapse.

KW - childhood acute lymphoblastic leukemia

KW - CNS prophylaxis

KW - reinduction therapy

KW - standard risk

KW - triple intrathecal therapy

UR - http://www.scopus.com/inward/record.url?scp=84990215128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990215128&partnerID=8YFLogxK

U2 - 10.1002/pbc.26142

DO - 10.1002/pbc.26142

M3 - Article

C2 - 27696656

AN - SCOPUS:84990215128

VL - 64

SP - 234

EP - 241

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -